Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-007819
Filing Date
2019-08-09
Accepted
2019-08-09 08:28:25
Documents
63
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q gemp-20190630x10q.htm 10-Q 1414430
2 EX-10.1 gemp-20190630ex1018d6234.htm EX-10.1 44171
3 EX-31.1 gemp-20190630ex3110af19e.htm EX-31.1 17957
4 EX-32.1 gemp-20190630ex321a997e6.htm EX-32.1 12148
  Complete submission text file 0001558370-19-007819.txt   4887073

Data Files

Seq Description Document Type Size
5 EX-101.INS gemp-20190630.xml EX-101.INS 827474
6 EX-101.SCH gemp-20190630.xsd EX-101.SCH 46436
7 EX-101.CAL gemp-20190630_cal.xml EX-101.CAL 27665
8 EX-101.DEF gemp-20190630_def.xml EX-101.DEF 145350
9 EX-101.LAB gemp-20190630_lab.xml EX-101.LAB 393136
10 EX-101.PRE gemp-20190630_pre.xml EX-101.PRE 278717
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 191011404
SIC: 2834 Pharmaceutical Preparations